Antihistamines are superior to topical steroids in managing Human Immunodeficiency Virus (HIV)-associated papular pruritic eruption

International Journal of Dermatology

Volumn 49, Issue 1, 2010, Pages 83-86

  Navarini, Alexander A ^a,b   Stoeckle, Marcel ^a,d   Navarini, Susanne ^a,e   Mossdorf, Erik ^a,d   Jullu, Boniphace S ^a   Mchomvu, Rehema ^a   Mbata, Marco ^c   Kibatala, Patience ^c   Tanner, Marcel ^d   Hatz, Christoph ^d   Schmid Grendelmeier, Peter ^b  

^a IFAKARA HEALTH INSTITUTE   (Tanzania)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c St Francis Designated District Hospital   (Tanzania)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; HYDROCORTISONE; PROMETHAZINE; STEROID;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; COMORBIDITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PAPULAR RASH; PREVALENCE; RETROSPECTIVE STUDY; RURAL AREA; SKIN PRURITUS; TANZANIA;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; EXANTHEMA; HISTAMINE ANTAGONISTS; HISTAMINE H1 ANTAGONISTS; HIV INFECTIONS; HUMANS; PROMETHAZINE; PRURITUS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; STEROIDS; TANZANIA; TREATMENT OUTCOME;

EID: 73149084835     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04279.x     Document Type: Article

References (11)

1. Piot P, Quinn TC, Taelman H. Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet 1984, 2:65-69.
2. Van de Perre P, Rouvroy D, Lepage P. Acquired immunodeficiency syndrome in Rwanda. Lancet 1984, 2:62-65.
3. Liautaud B, Pape JW, DeHovitz JA. Pruritic skin lesions. A common initial presentation of acquired immunodeficiency syndrome. Arch Dermatol 1989, 125:629-632.
4. Hira SK, Ngandu N, Wadhawan D. Clinical and epidemiological features of HIV infection at a referral clinic in Zambia. J Acquir Immune Defic Syndr 1990, 3:87-91.
5. Bason MM, Berger TG, Nesbitt LT. Pruritic papular eruption of HIV-disease. Int J Dermatol 1993, 32:784-789.
6. Teofoli P, Barbieri C, Pallotta S. Pruritic eosinophilic papular eruption revealing HIV infection. Eur J Dermatol 2002, 12:600-602.
7. Hevia O, Jimenez-Acosta F, Ceballos PI. Pruritic papular eruption of the acquired immunodeficiency syndrome: a clinicopathologic study. J Am Acad Dermatol 1991, 24:231-235.
8. Ishii N, Nishiyama T, Sugita Y. Pruritic papular eruption of the acquired immunodeficiency syndrome. Acta Derm Venereol 1994, 74:219-220.
9. Berman B, Flores F, Burke G. Efficacy of pentoxifylline in the treatment of pruritic papular eruption of HIV-infected persons. J Am Acad Dermatol 1998, 38:955-959.
10. Resneck JS, Van Beek M, Furmanski L. Etiology of pruritic papular eruption with HIV infection in Uganda. JAMA 2004, 292:2614-2621.
11. Castelnuovo B, Byakwaga H, Menten J. Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome? AIDS 2008, 22:269-273.